Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	9/20/2006 11:38:41 AM
	of 3044

Millennium Pharmaceuticals "neutral," estimates reduced Wednesday, September 20, 2006 4:07:45 AM ET Robert W. Baird NEW YORK, September 20 (newratings.com) - Analysts at Robert W Baird maintain their "neutral" rating on Millennium Pharmaceuticals Inc (MLNM.NAS), while reducing their estimates for the company. The target price is set to $11. In a research note published yesterday, the analysts mention that the company expects to report a sequential decline in its revenues during 3Q06. The analysts expect Velcade to, however, deliver robust growth going forward on account of an increase in front-line setting uptake. The EPS estimates for 2006, 2007 and 2008 have been reduced from $0.07 to $0.05 and from $0.17 to $0.15 and from $0.30 to $0.29 respectively.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next